The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from GlobeNewswire (a Nasdaq OMX company)

Prothena Corporation plc [PRTA] to Ring The NASDAQ Stock Market Opening Bell

Tuesday, February 12, 2013

Prothena Corporation plc [PRTA] to Ring The NASDAQ Stock Market Opening Bell06:00 EST Tuesday, February 12, 2013 ADVISORY, Feb. 12, 2013 (GLOBE NEWSWIRE) --What: Prothena [PRTA], a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, Dale Schenk, CEO will ring the Opening Bell.Where: NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen: Wednesday, February 13, 2013 – 9:15 a.m. to 9:30 a.m. ET     Contact: Paul Cox (212) 362-1200 Paul@sternir.comNASDAQ MarketSite:Jen Knapp (212) 401-8916 Jennifer.knapp@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSKFacebook and Twitter: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.                   For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.Webcast: A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.                              About Prothena Corporation plc [PRTA]: Prothena Corporation plc (Nasdaq:PRTA) is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion, particularly on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis, Parkinson's disease and related synucleinopathies, and novel cell adhesion targets involved in autoimmune disease and metastatic cancers. For more information, please visit www.prothena.com.About NASDAQ OMX Group: The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 23 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99+% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (www.facebook.com/NASDAQ) and Twitter (www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500) -NDAQA-